Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)
| Journal | Volume 83 - 2020 |
| Issue | Fasc.1 - Original articles |
| Author(s) | C. Reenaers 1, A. Cremer 2, O. Dewit 3, B. De Vroey 3 4, W. Van Moerkercke 5, P. Bossuyt 6, V. Muls 7, J. Imschoot 8, S. Block 8, A. Hantson 8, P. Van Hootegem 9 |
| Full article |
 PAGES 15-23 VIEW FREE PDF |
|
Affiliations: (1) Centre Hospitalier Universitaire de Liège, Avenue de l’Hôpital 1, 4000 Liège, Belgium
(2) Cliniques Universitaires de Bruxelles, Hôpital Erasme, Brussels, Belgium (3) Clinique Universitaire Saint-Luc, Brussels, Belgium (4) Centre Hospitalier Jolimont, Haine-Saint-Paul, Belgium (5) Algemeen Ziekenhuis Groeninge, Kortrijk, Belgium (6) Imelda GI Clinical Research Centre, Bonheiden, Belgium (7) Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium (8) Takeda Belgium, Zaventem, Belgium (9) Algemeen Ziekenhuis Sint-Lucas Brugge vzw, Brugge, Belgium |
|
Background and study aims: Vedolizumab (VDZ) is a gutselective integrin inhibitor used to treat Crohn’s disease (CD) and ulcerative colitis (UC). This retrospective study assessed effectiveness and treatment persistence of VDZ in a Belgian real-life cohort of CD and UC patients. Patients and methods: CD and UC patients from 15 Belgian centers, who started VDZ between 01/09/2015 and 31/06/2016 and attended ≥1 visit after the first VDZ infusion, were included. Data were collected before first infusion, at week (W)10, W14 (CD patients only), month (M)6 and last follow-up. Treatment response and remission rates (changes in disease activity scores) and treatment persistence (Kaplan-Meier analysis) were assessed. Results: Of the 348 patients receiving at least one dose of VDZ, 325 (202 CD, 45 biologic-naïve; and 123 UC, 42 biologic-naïve) patients were included in data analyses. At M6, 87.6% (176/201) of CD and 86.1% (105/122) of UC patients were still on VDZ treatment, 75.6% (34/45) and 83.9% (26/31) achieved clinical response, and 66.7% (44/66) and 42.9% (15/35) were in remission. At M6 remission rates was significantly higher while response rates tended to be higher among biologic-naïve versus biologic-failure CD patients. Conclusions: VDZ offers an effective treatment option in real-life settings and treatment effectiveness appears higher in biologic-naïve versus biologic-failure CD patients. Keywords: vedolizumab, real-life, treatment persistence, effectiveness, treatment predictors, inflammatory bowel disease. |
|
© Acta Gastro-Enterologica Belgica. PMID 32233267 |
